Literature DB >> 32992061

Letter to the Editor Regarding "COVID-19 Impact on Neurosurgical Practice: Lockdown Attitude and Experience of a European Academic Center".

Nishant Goyal1, Kanav Gupta2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32992061      PMCID: PMC7521373          DOI: 10.1016/j.wneu.2020.09.117

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


× No keyword cloud information.
We read with great interest the article by Lubansu et al, “COVID-19 impact on neurosurgical practice: lockdown attitude and experience of a European academic center.” In their article, the authors shared their experience during the coronavirus disease of 2019 (COVID-19) pandemic in Belgium and discussed their institute protocol and workflow for treatment of neurosurgical patients. In Belgium, the first patient with COVID-19 was reported on February 4 and the first COVID-19–related death was confirmed on March 11, 2020. As a response to the pandemic, certain measures were taken at their institute, including the use of tele-medicine, the replacement of meetings and physical classes with video-conferences or webinars, and implementation of a social distancing policy. Non-urgent elective surgeries and outpatient activities were suspended. Wards, resources, and teams were redeployed in anticipation of the potential congestion according to the latest national and institutional forecasts. Because surgical activity was reserved for critical and semi-urgent surgeries, the total number of operated patients decreased from 308 to 154 (−50%), and emergent surgeries decreased from 75 to 29 compared with a similar period in 2019. The COVID-19 pandemic has been sweeping across the world and has stretched the capacities of health-care systems globally. As of September 18, 2020, India's tally of confirmed COVID-19 cases had reached 5,130,305, making it the second most affected country in terms of absolute numbers, with 84,372 COVID-19–related deaths, the third highest after the United States and Brazil. , Since the onset of the pandemic in our country, we adopted measures very similar to those outlined by Lubansu et al, including the use of telemedicine, webinars, social distancing policies, appropriate modifications in operating rooms, creation of dedicated COVID-19 areas, and suspension of nonemergent surgeries.4, 5, 6, 7, 8, 9, 10 Our department has seen a major change in the volume and spectrum of patients treated. During the period of lockdown in India (March 25 to May 31, 2020), our surgical volume decreased from 111 to 53 (−52.3%), although the number of emergent surgeries remained the same (47 cases), compared with the same period in 2019. Thus, we were able to continue providing emergency services even during the lockdown, although most of the “nonemergent” cases had been postponed or cancelled. Similarly, a large number of elective or "non-emergent" surgeries were cancelled or postponed in hospitals across the world in response to the COVID-19 pandemic.10, 11, 12, 13, 14, 15, 16, 17, 18, 19 We adopted an institute policy of testing all patients admitted to the ward and, now, test them once more before surgery. , Thus, we have been considering every patient admitted to the hospital as suspected of having COVID-19. This policy of universal testing is important owing to the highly infective nature of the virus. The performance of 2 tests before surgery has reduced the false-negative findings from 29% to 8.41%, because the sensitivity of the tests available is only 71%. If the need for emergent surgery does not allow for preoperative COVID-19 testing, the patient will undergo surgery in a dedicated COVID-19 operating room with the necessary COVID-19 precautions. Such patients then undergo COVID-19 testing postoperatively and will be moved to a non–COVID-19 area if the test result is negative. We believe that our policy of COVID-19 testing and strict quarantine and isolation rules have been instrumental in allowing us to maintain the infection rate in our health care personnel to an acceptable level, allowing continued functioning in the hospital. , According to Lubansu et al, the Belgium's health ministry guidelines have reserved COVID-19 testing for patients requiring hospital admission and suspected of having COVID-19. The same is apparent in their institute protocol, because they seemed to rely heavily on the findings from computed tomography of the chest, with COVID-19 testing limited to suspected patients only and not performed for all patients. Despite this, 20 of 176 patients (11.4%) admitted for neurosurgery tested positive for COVID-19 in their study. Thirteen patients (65%) in the COVID-19 group had presented with stroke compared with 17% in the non–COVID-19 group. The mortality rate was remarkably high at 45% and even higher for patients requiring surgical intervention (77%; 7 of 9 patients). In contrast, from April to August 2020, we had 284 neurosurgical admissions, with only 6 patients (2.1%) testing positive for COVID-19. Only 1 patient had presented with stroke (patient 2). Three patients had undergone surgical intervention, two had received conservative treatment, and one had refused surgery (Table 1 ). We have a policy to postpone surgery for COVID-19–positive patients when the situation permits. This policy has been supported by a seminal report. which showed that in patients with perioperative COVID-19 infection, the 30-day mortality after elective surgery was 23.8%, with pulmonary complications occurring in 51.2%. Two patients (patients 5 and 6) requiring surgery had tested positive for COVID-19 preoperatively. For both patients, the surgery was performed only after isolating the patients for 14 days in a dedicated COVID-19 area and after 3 consecutive negative test results. None of the 6 patients with COVID-19 in our series had died.
Table 1

Details of Neurosurgical Patients Who Tested Positive for COVID-19

Pt. No.Age; SexDiagnosisComorbiditiesManagementOPD; EmergencyCOVID-19 Test ResultsOutcome at Discharge
147; MC5–C7 intradural extramedullary tumorNoneRefused surgeryOPDPositive at admission; isolated, tested negative; advised surgery, refused; discharged against medical adviceSame
260; MLeft thalamic bleeding with intraventricular extensionDiabetes, hypertensionConservativeEmergencyTested positive 3 times at admission; isolated, tested negative twiceImproved
315; MSevere traumatic brain injury (right frontal contusion with diffuse axonal injury)Familial adenomatous polyposisConservativeEmergencyTested positive twice; isolated, tested negative onceImproved
480; MLeft chronic subdural hematoma with mass effectNoneLeft frontal and parietal burr hole and drainageEmergencyTested negative preoperatively; surgery; tested positive in postoperative period; isolated, tested negative twiceImproved
528; FOperated case of medulloblastoma with spinal metastasis (received adjuvant radiochemotherapy)Pregnant (24 weeks' gestation)T11-T12 laminectomy and excision of spinal metastasisOPDTested positive preoperatively; isolated, tested negative 3 times; surgeryImproved
642; MLeft posterior third parasagittal meningiomaNoneLeft parieto-occipital craniotomy and Simpson grade 3 tumor excisionEmergencyTested positive twice preoperatively; isolated, tested negative 3 times; surgeryImproved

Pt. No., patient number; OPD, outpatient department; COVID-19, coronavirus disease 2019; M, male; F, female.

Details of Neurosurgical Patients Who Tested Positive for COVID-19 Pt. No., patient number; OPD, outpatient department; COVID-19, coronavirus disease 2019; M, male; F, female. This difference in the proportion of COVID-19 positivity and low mortality rate among patients can be attributed to the different genetics and immune system responses, regional contrasts in obesity levels and general health, in addition to the quick reaction time to the crisis in India. In addition, the coronavirus strains prevalent in India and China appear to be less virulent than the strains isolated from Italy, Spain, and the United States. The number of COVID-19–related deaths per 1 million population for India and China, South Korea and Indonesia, Pakistan, Japan, and Thailand was 3, 5, 7, 6, and <1, respectively. In contrast, the number of COVID-19–related deaths per 1 million population in Germany, Canada, the United States, and Britain, Italy, and Spain ∼100, ∼180, nearly 300, and >500, respectively. Belgium has witnessed a high number of deaths per 1 million inhabitants (801 per 1 million) and a case-fatality ratio of 16.3%. It would also be interesting to know whether the patients with COVID-19 reported by Lubansu et al had undergone surgery immediately or after isolation and with negative COVID-19 test results, because the perioperative mortality has been significantly greater for patients with perioperative COVID-19 infection. In addition, it would be interesting to know how many of the 176 patients had actually undergone testing for COVID-19.
  4 in total

1.  Letter to the Editor Regarding "Early Changes to Neurosurgery Resident Training During the COVID-19 Pandemic at a Large United States Academic Medical Center".

Authors:  Nishant Goyal; Jitender Chaturvedi; P Prarthana Chandra; Amol Raheja
Journal:  World Neurosurg       Date:  2020-11-14       Impact factor: 2.104

2.  Letter to the Editor Regarding "Impact of COVID-19 on Neurosurgical Training in Southeast Asia".

Authors:  Nishant Goyal; Tejas Venkataram; Chinmaya Dash; P Prarthana Chandra
Journal:  World Neurosurg       Date:  2021-02       Impact factor: 2.104

3.  "Locked up inside home" - Head injury patterns during coronavirus disease of 2019 pandemic.

Authors:  Nishant Goyal; Srikant Kumar Swain; Kanav Gupta; Jitender Chaturvedi; Rajnish Kumar Arora; Suresh K Sharma
Journal:  Surg Neurol Int       Date:  2020-11-18

4.  Letter to the Editor Regarding "Neurosurgery Services in Dr. Sardjito General Hospital, Yogyakarta, Indonesia, During the COVID-19 Pandemic: Experience from a Developing Country".

Authors:  Nishant Goyal; Jitender Chaturvedi; P Prarthana Chandra; Amol Raheja
Journal:  World Neurosurg       Date:  2021-02       Impact factor: 2.104

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.